Market Highlights
Cervical cancer is a cancer of cervix in women and is of three types namely squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas. The disease is characterized by uncontrolled growth of cells. Various types of surgeries such as cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, and trachelectomy are available for the treatment of cervical cancer. Additionally, radiation therapy, chemotherapy, targeted therapy, and hormone therapy are also used for the treatment of the disease.
The global cervical cancer treatment market is determined by an increasing prevalence of cervical cancer, increasing awareness about women health, and the increasing demand for innovative diagnostic devices by healthcare professionals. However, the high cost of treatment is a major restraint for the market growth.
Global cervical cancer treatment market is expected to grow at a CAGR of 6.5% during the forecast period.
Taste the market data and market information presented through more than 120 market data tables and figures spread over 200 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Cervical Cancer Treatment Market research report–Global forecast till 2023.”
Request For Sample Report: https://www.marketresearchfuture.com/sample_request/5834
Major Players in the Cervical Cancer Treatment Market
Some of the key players in the global market are Pfizer Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, ALLERGAN, Actavis Pharma Company, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc, Hetero, Biocon, Novartis, Genentech USA, and others.
Segmentation
The global cervical cancer treatment market is segmented on the basis of type, treatment, and end-user.
On the basis of type, the market is segmented into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas.
On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy, and others.
Surgery is further segmented into cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, trachelectomy, and others. The radiation therapy is further segmented into external beam radiation and brachytherapy. Chemotherapy is further segmented into cisplatin, carboplatin, paclitaxel, doxorubicin, gemcitabine, bevacizumab, and others. Targeted therapy is further segmented into bevacizumab and pazopanib. Hormone therapy is further segmented into oestrogen, progesterone, progestogens, and testosterone.
Table Of Content:
1.Report Prologue
- Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
- Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
- Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
- Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
